The advance represents the first cancer-care pathway offering an automatically combined analysis of morphological, molecular and histological data. 

The COVID crisis has spurred clinical researchers to look myriad ways AI might help win the war against the virus. Has the investigatory boomlet ended up raising as many nettlesome concerns as positive possibilities?

Emergency-room patients are happy to receive care from a physician interacting remotely over a tablet computer mounted on a dog-like robot.

The FDA has cleared an AI tool that helps radiologists diagnose or rule out prostate cancer on MRI scans.

Harvard researchers have used machine learning to find molecular features in existing drugs that may be effective in warding off or treating Alzheimer’s disease.

Researchers in Italy have demonstrated a no-cost, AI-based technique for detecting the presence of previously undiagnosed abnormalities in blood sugar stability.

Clinical laboratories store a motherlode of objective and structured patient data well primed for mining with AI. Given this reality, pathologists and medical laboratorians must set and abide by principles guiding the ethical use of the technology.

A survey of ICU doctors and nurses at Mayo Clinic reveals widespread concern over lawsuits connected to the proposed use of video recording and video recognition with computer vision.

If verified in additional trials, the advance will facilitate care planning much earlier than the current average age of diagnosis, 4 years old.

Several issues with AI can “make people suspicious” of the technology when applied to healthcare, according to the Consumer Technology Association.